She had five close friends. She told one.
Not because she doubted the prescription. Her GP had raised tirzepatide after her bloodwork showed worsening insulin resistance, and the decision followed a real clinical conversation. She told one friend because she did not know what the truth might do to the other four relationships.
Would her weight loss still count? Would lunch become surveillance? Would every smaller portion be treated as evidence? Would her friends think she had cheated, become vain, or surrendered to a lifetime of medication?
She was not deciding whether the treatment was legitimate. She was deciding whether the friendship was safe enough for the truth.
Real physician voices, twice a week
Free, and one click to unsubscribe.
That quiet calculation tells us where weight stigma lives now.
In the 1980s and 1990s, a larger body was routinely read as evidence: too much appetite, too little control, insufficient effort. Weight loss was expected to look like discipline made visible: restriction, exercise, and the public performance of trying hard enough.
Glucagon-like peptide-1 (GLP-1) medicines are not the 1990s diet-pill era repeated. Their mechanisms, evidence base, and legitimate clinical indications differ. But they entered a culture that still treats weight as a referendum on character. They changed the biological possibilities. They did not erase the moral test. They added another one.
People are still judged for living in larger bodies. Now they may also be judged for the route by which their body changes. Lose weight without medication, and you are disciplined. If you use medication, you have taken the easy way out. Lose a great deal and people decide you have gone too far. Regain after treatment stops and the return of weight is treated as exposure (proof that the success was never really yours).
There is no compliant body in this system. The rules simply move.
Emerging research is beginning to document what patients already describe. In a 2026 qualitative study of 30 GLP-1 users (most of whom had type 2 diabetes), participants reported being seen as cheating or taking the easy way out. Some emphasized their diabetes diagnosis to make their treatment seem more acceptable. Fear of judgment restricted what they shared and with whom.
In a separate experimental study, people who lost the same amount of weight were judged differently according to how they lost it. GLP-1-supported weight loss attracted more negative judgments than diet-and-exercise weight loss. The outcome was identical. The moral value assigned to it was not.
The message is difficult to miss: Weight loss counts most when other people can see that you suffered for it.
This does not stay in the social world. It enters the treatment room.
When patients believe their medication must be defended, honest disclosure becomes harder. They may lead with protein, walking, and lifestyle changes, then mention the medication apologetically, or not at all. A person who feels ashamed of needing treatment may also find it harder to say that nausea is becoming unmanageable, that eating has become frightening, that side effects are affecting work, or that cost and access are threatening continuity.
Silence is not the same as stability.
I know both sides of that silence. As a registered nurse, I understand the need for careful assessment, monitoring, and attention to nutrition, muscle, side effects, and vulnerability to disordered eating. As a GLP-1 patient, I know what the consultation cannot measure unless someone asks.
The first change I noticed was not on the scale. It was the quiet. Food stopped occupying so much space in my head. That relief came with fatigue, dry mouth, brain fog, and the slow work of learning what my body needed now. Nothing about it was effortless. It was treatment. Helpful. Imperfect. Mine.
I also know how early the lesson begins. I was eleven when I attended a doctor for a sore throat and left with a verdict about my body. The doctor spoke to my mother while I sat beside her. I did not hear clinical advice. I heard that my body had entered the room before my symptom and that it could become the explanation for almost anything.
Decades later, the language is more sophisticated. The emotional lesson is remarkably familiar: Your body is public evidence, and other people are entitled to decide what it says about your character.
Clinicians cannot remove every judgment a patient will meet, but we can stop reproducing it. At follow-up, do more than record weight and side effects. Ask, “Has this treatment changed how you feel about your body, your eating or being seen by other people?” Ask who knows. Ask whether secrecy is costing the patient support. Ask what they fear would happen if access stopped or weight returned.
Those questions are not an optional kindness. They are part of understanding the environment in which treatment must succeed.
Why did she tell only one of five friends? Because she was not simply disclosing medication. She was testing whether she could tell the truth and remain safe in the relationship.
The prescription was new. The fear was not. She was still asking the oldest question weight stigma teaches: If you know what it took to change my body, will you think less of me?
A prescription can change biology. It cannot, by itself, answer the question shame has taught the patient to ask.
This essay is cited in the KevinMD record on GLP-1 drugs.
Patience C. Ennis is a registered nurse, author, Results Coach, glucagon-like peptide-1 (GLP-1) user, and the founder of Body Compass, an education and navigation platform for people living with, considering, or moving beyond GLP-1 treatment. A graduate of King’s College London, she draws on more than three decades of clinical experience across emergency, community, palliative, and aged care, bringing together clinical knowledge, lived experience, and patient education to address the questions that often sit beyond the prescription.
Through Body Compass, she develops evidence-informed resources, books, practical tools, news updates, and non-clinical coaching support designed to help people understand changing appetite, side effects, strength, food noise, treatment adaptation, maintenance, and stopping. Her work is grounded in clarity, dignity, and honest interpretation of evidence, without hype, shame, or false certainty. Her aim is not to tell people what to decide, but to help them understand the terrain, ask better questions, and navigate metabolic health with greater confidence in everyday life and care.
She is the author of When GLP-1 Feels Different: Plateau, Food Noise, Adaptation and the Fear of “Resistance” (2026), available on Amazon and through Body Compass. Her other titles include Living Well on GLP-1 Medication: A Practical Guide to Everyday Life Beyond the Prescription, The Body Compass 30-Day Navigation Diary: A Reflective Daily Companion for GLP-1 Treatment, and The 30-Day GLP-1 Navigation Companion: Observation, Reflection, Preparation, Navigation.
She shares updates on LinkedIn, Facebook, the Body Compass Facebook page, Instagram, X, TikTok, and YouTube.
